NOT FOR HUMAN CONSUMPTION

"Frag 17–24" refers to the actin-binding core motif of thymosin β4 (Tβ4), the octa/heptapeptide sequence around residues 17–24 (canonical: LKKTETQE / 17–23 LKKTETQ). This short fragment retains key cell-migration and cytoskeletal activities attributed to full-length Tβ4 and is used in research under the colloquial name TB-500 (a Tβ4-derived fragment). It is explored for wound repair, tendon/ligament recovery, angiogenesis, and anti-inflammatory remodeling. No product in this class is FDA/EMA-approved.

Additional Benefits of Tβ4 Frag 17–24 (TB-500-class) Now Under Investigation

Benefit	Key take-aways
1 Accelerated wound closure & re-epithelialization	Fragment promotes keratinocyte migration, lamellipodia formation, and granulation tissue; topical or perilesional dosing shortens time-to-closure in animal cutaneous wounds. <br/><em>Wound Repair & Regeneration; Journal of Investigative Dermatology</em>
2 Angiogenesis & perfusion restoration	Up-regulates VEGF, HIF-1α, and endothelial outgrowth, improving microvascular density in ischemic tissue models. <br/><em>Circulation Research; Angiogenesis</em>
3 Tendon/ligament healing	Enhances tenocyte migration, collagen I/III alignment, and mechanical strength post-injury; synergy reported with eccentric-loading rehab. <br/><em>American Journal of Sports Medicine; Journal of Orthopaedic Research</em>
4 Anti-inflammatory remodeling	Dampens NF-κB/TNF-α/IL-1β and shifts macrophages toward pro-resolving phenotypes, reducing edema and scar thickness. <br/><em>Journal of Immunology; Inflammation Research</em>
5 Cardioprotection (preclinical)	In myocardial I/R and chronic ischemia models, Tβ4-motif peptides reduce apoptosis, enhance Akt/ILK signalling, and limit fibrosis, improving function. <br/><em>Circulation; Cardiovascular Research</em>
6 Corneal/ocular surface repair	Speeds corneal epithelial healing and nerve regeneration with improved tear-film metrics in dry-eye/keratitis models. <br/><em>Investigative Ophthalmology & Visual Science; Cornea</em>
7 Skeletal muscle regeneration	Augments satellite-cell migration, myotube formation, and vascular support after contusion/strain. <br/><em>FASEB Journal; Muscle & Nerve</em>
8 Anti-fibrotic signaling	Lowers TGF-β/CTGF and disordered collagen deposition in skin and tendon, yielding more elastic scars. <br/><em>Matrix Biology; Fibrogenesis & Tissue Repair</em>
9 Hair-follicle cycling (exploratory)	Tβ4-derived sequences can activate anagen, increase VEGF around follicles, and improve shaft calibre in murine models. <br/><em>Experimental Dermatology; Dermatologic Therapy</em>

2. Molecular Mechanism of Action

2.1 Receptor/Target Pharmacodynamics

The LKKTETQ(E) motif binds G-actin, modulating actin sequestration and polymerization. Downstream, it engages integrin-linked kinase (ILK) and PI3K–Akt, influences focal-adhesion dynamics (FAK/vinculin), and induces MMP-2/9 for controlled matrix remodeling. Indirect effects include VEGF/HIF-1α induction and NF-κB tempering in inflamed tissue.

2.2 Down-stream Biology

Pathway	Functional outcome	Context
Actin–ILK–Akt	Cell migration, survival, cytoskeletal repair	Keratinocytes, tenocytes, endothelium
FAK/MMP program	Matrix remodeling, sprouting angiogenesis	Wound bed, tendon/ligament
HIF-1α → VEGF	Neovascularization, improved perfusion	Ischemic tissue, cornea
NF-κB down-tuning	↓ TNF-α/IL-1β, pro-resolving macrophages	Inflamed wounds, tendon sheath
TGF-β/CTGF restraint	↓ pathologic fibrosis, better collagen alignment	Scar/Tendon matrix

3. Pharmacokinetics

Route/formulations: Investigated subcutaneous/perilesional injections, topical gels/eye drops, and biomaterial dressings.
Half-life: Short (minutes–hours); biological effects persist via transcriptional and matrix changes.
Distribution: Predominantly local; systemic exposure limited unless high/IV doses used.
Clearance: Peptidase degradation; no CYP interactions expected.

4. Pre-clinical and Translational Evidence

4.1 Cutaneous & Soft-tissue Repair

Multiple rodent and porcine models show faster closure, improved tensile strength, and reduced scar with fragment dosing vs control, paralleling full-length Tβ4.

4.2 Musculoskeletal

In tendon laceration/overuse models, fragment treatment improved collagen fibre orientation and load-to-failure; functional recovery was enhanced when combined with graded loading.

4.3 Ocular Surface

Topical derivatives accelerated corneal re-epithelialization, decreased pain/staining, and supported subbasal nerveregrowth.

Evidence quality note: Most data are pre-clinical or early clinical/ophthalmic pilot; standardized, placebo-controlled human trials for musculoskeletal uses remain limited.

5. Emerging Clinical Interests

Field	Rationale	Current status
Chronic wounds (DFU/VLU)	Pro-migration + antibiofilm-friendly remodeling	Early clinical/feasibility
Tendon/ligament rehab	Faster matrix repair with better alignment	Pre-clinical → small series
Corneal disease/dry eye	Epithelial/nerve repair	Early ophthalmic pilots
Cardiac ischemia	Cytoprotection + microvascular support	Pre-clinical
Scar modulation	Anti-fibrotic remodelling	Pre-clinical/observational

6. Safety and Tolerability

Common (local): Mild injection-site irritation or stinging with topicals; transient erythema.
Systemic: Limited data; short peptides generally well tolerated in animals at research doses.
Theoretical cautions: Pro-angiogenic activity may be undesirable in active malignancy or proliferative retinopathies; monitor for exuberant granulation in high-dose topical use.
Quality/purity: Grey-market products vary; prefer GMP-grade materials in research.

Comparative safety matrix

Concern	Tβ4 Frag 17–24 (TB-500-class)	Full-length Tβ4 (43 aa)	BPC-157
Size/PK	Short; very rapid clearance	Longer; still short-lived	Short; GI stability claims (preclinical)
Angiogenesis	Yes (VEGF/HIF-1α)	Yes (often stronger)	Context-dependent
Tendon/ligament data	Good preclinical	Robust preclinical	Good preclinical
Human evidence	Sparse/early	Early ophthalmic/derm pilots	Sparse/heterogeneous
Regulatory status	Not approved	Not approved	Not approved

7. Regulatory Landscape

Approvals: None in major markets.
Access: Research/compounded channels; WADA generally prohibits non-approved growth-repair peptides under S0.
Clinical development: Ophthalmic/topical formulations of Tβ4-derived peptides are the furthest along; musculoskeletal indications lack pivotal trials.

8. Future Directions

Formulation engineering: Hydrogels, microneedles, collagen scaffolds, or slow-release depots to extend local exposure.
Head-to-head trials: Fragment vs full-length Tβ4 vs standard care in DFU/VLU and Achilles/rotator-cuffrepair.
Mechanistic biomarkers: MMP-2/9 activity, VEGF, angiographic perfusion, shear-wave elastography, and patient-reported function.
Combination therapy: Pair with eccentric loading, PRP, or LL-37-based wound care for antibiofilm + pro-healing synergy.
Safety surveillance: Focus on angiogenesis-related risks, ocular neovascularization, and tumour surveillancein long-term use.

Selected References

Wound Repair & Regeneration; Journal of Investigative Dermatology, Cutaneous healing and keratinocyte migration with Tβ4 motifs.
Circulation; Cardiovascular Research, Cytoprotection/angiogenesis in ischemic models.
American Journal of Sports Medicine; Journal of Orthopaedic Research, Tendon/ligament repair biomechanics under Tβ4-derived peptides.
Investigative Ophthalmology & Visual Science; Cornea, Corneal epithelial/nerve repair with Tβ4 derivatives.
Journal of Immunology; Inflammation Research, NF-κB modulation and macrophage polarization.
Matrix Biology; Fibrogenesis & Tissue Repair, Anti-fibrotic remodeling pathways.
FASEB Journal; Muscle & Nerve, Skeletal muscle regeneration and satellite-cell migration.

Thymosin β4 Fragment 17–24 10mg vial

Complete the setup